FDA Publishes Draft Guidance on Cosmetic Product Facility Registration and Cosmetic Product Listing
On August 7, 2023, the Food and Drug Administration (FDA) published Draft Guidance for Industry: Registration and Listing of Cosmetic Product Facilities and Products (the...
Part 3 in MoCRA Series: FDA Guidance on Cosmetic Product Listings | Bryan Cave Leighton Paisner
The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) is is the most significant expansion of FDA’s authority to regulate cosmetics since the Federal Food, Drug, and...
Part 2 in MoCRA series: FDA guidance on facility registrations | Bryan Cave Leighton Paisner
The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) is significantly changing regulation of the cosmetics industry in the U.S. For the first time, cosmetics...
New Cosmetics Regulatory Scheme to Reshape Industry’s Relationship with FDA
Under MoCRA, cosmetic companies are required to register, list products, comply with good manufacturing practices (GMPs), develop safety data, include a domestic address and contact...
FDA bans 8 beauty products from Japan
MANILA, Philippines - Eight Japanese beauty products containing substances that can cause uneven skin coloring have been banned. The Food and Drug Administration (FDA) recalled...
Cosmetic Companies FDA Modernization of Cosmetics Regulation Act
OVERVIEW The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) went into effect with US President Joe Biden’s signing of the Consolidated Appropriations Act, 2023....
USP, FDA Propose Quality Standards for Cannabis, Highlighting its Role as Medicine
US Pharmacopeia (USP) is championing cannabis quality standards with a proposed new cannabis monograph that recently closed for public comment.1 USP’s first cannabis monograph was...
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA , was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trialModerna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK),...
A Tiny Lab Finds Danger on Drugstore Shelves While the FDA Lags Behind
(Bloomberg) -- David Light can’t wait to show off his tchotchkes. The curly haired scientist lights up with boyish enthusiasm when he picks up a...
The FDA sets its sights on CBD food products | Reed Smith
In late November, the U.S. Food and Drug Administration (FDA) sent a new round of warning letters to companies manufacturing and marketing cannabidiol (CBD) products....